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Protein kinase R (PKR), a sensor of double-stranded RNA, plays an important role in the host response to
viral infection. Hepatitis C genotype 2a virus (HCV2a) has been shown to induce PKR activation to
suppress the translation of antiviral interferon stimulated genes (ISGs), suggesting that PKR inhibitor
can be beneﬁcial for treating chronically HCV-infected patients in conjunction with interferon alpha
and ribavirin. However, in this study, we found that PKR inhibition using siRNA PKR, shRNA PKR or PKR
inhibitor enhanced HCV 1a replication and rendered Huh7.5.1 cells more susceptible to HCV1a
infection. Additionally, PKR silencing suppressed NF-kB activation and NF-kB mediated STAT1
phosphorylation in Huh7.5.1 cells and HCV1a persistently infected Huh7.5.1 cells (2HDD4). These
effects were accompanied by a reduction of interferon beta response and thereby enhanced HCV1a
replication in Huh7.5.1 cells. We conclude that host cells can employ PKR activation to restrict HCV1a
replication through regulation of NF-kB expression.
Published by Elsevier Inc.Introduction
The innate immune system plays a critical role in containing early
hepatitis C virus (HCV) infection through the induction of type
1 interferon and the up-regulation of interferon stimulated genes.
However, because HCV replicates very rapidly, peak levels of virus are
achieved within the ﬁrst days of infection and the HCV proteins
subsequently generated (core, NS2, NS3, NS4B, NS5A) can inhibit
many steps in the innate immune response, preventing the activation
of NF-kB and facilitating viral replication (Joo et al., 2005; Park et al.,
2012). The net effect is that HCV generally circumvents both the
innate response and the adaptive immune response resulting in
persistent infection in 75–85% of those infected.
In response to viral infection, the transcription of interferon beta is
initiated by enhancesome formation that consists of multiple tran-
scriptional factors including ATF-2/c-Jun, IRF3/IRF7 and NF-kB (Ford
and Thanos, 2010; Randall and Goodbourn, 2008). NF-kB is the most
critical transcription factor in the regulation of interferon beta and
interferon simulated genes (ISGs) and is composed of ﬁve elements:Inc.
dicine, Building 10, Room 1C-
States. Fax: þ1 301 402 1360.RelA, cRel, RelB, p50 and p52. Through the Rel homology domain,
these elements can form homodimers and heterodimers. The cano-
nical pathway to NF-kB activation is initiated when upon stimulation
by LPS, polyI/C, TNF-alpha or viral infection. Then, IkB is phosphory-
lated leading to the translocation of the RelA (p65) component of NF-
kB into the nucleus (Hacker and Karin, 2006; Ting et al., 2010).
Subsequently, p65 serves as an immediate early transcription acti-
vator of interferon beta gene expression and production (Hiscott et al.,
2006). In order to antagonize the antiviral effect of interferon beta,
viruses have developed many strategies, especially concentrating on
inhibiting the activation of NF-kB.
PKR, the sensor of double-stranded RNA (dsRNA), also plays an
important role in the antiviral response through phosphorylation of
eIF2alpha and inhibition of host cell gene translation and protein
synthesis (D’Acquisto and Ghosh, 2001; Robertson and Mathews,
1996; Williams, 2001). DsRNA-activated PKR can induce the degrada-
tion of IkB resulting in the activation of NF-kB (Zamanian-Daryoush
et al., 2000). PKR has also been shown to be responsible for virus-
induced NF-kB activation in engineered vaccinia virus or attenuated
Herpes simplex virus-1 infected cells (Lynch et al., 2009; Taddeo et al.,
2003). In HCV infection, genetic analysis has shown that the HCV
internal ribosomal entry site (IRES) and the core and NS5A proteins
contain PKR-binding domains that are critical to PKR function
(Gimenez-Barcons et al., 2005; Toroney et al., 2010; Yan et al.,
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(Oem et al., 2008), suggesting that PKR is essential to the host’s
antiviral response to HCV infection. Thus, HCV infection can lead to a
duality of responses and the relative balance can result in either viral
clearance or persistence. On the one hand, virus-induced activation of
NF-kB can trigger the transcription of IL8, TNF-alpha and interferon
beta, which results in restriction of viral replication (Frey et al., 2009;
Hassan et al., 2007; Oem et al., 2008), conversely, HCV proteins can
diminish NF-kB activation, facilitating viral persistence. Integral to
this equation are virus-induced PKR activation and NF-kB activation.
In this study we show that the PKR silencing contributes to HCV1a
replication in HCV1a persistently infected Huh7.5.1 cells (2HDD4).
Moreover, PKR silencing inhibits the interferon beta response in PKR
silenced 2HDD4 cells through NF-kB inactivation. Consistent with this
mechanism, shRNA PKR renders cells more susceptible to HCV1a
infection in naı¨ve cells. In addition, NF-kB inhibitor improved HCV1a
replication in 2HDD4 cells. Hence, host defenses may be attenuated
by PKR silencing, enhancing HCV1a replication through the attenua-
tion of the NF-kB mediated interferon beta response.Fig. 1. siRNA PKR efﬁciently inhibited the activation of PKR. (A) HCV persistently
infected Huh7.5.1 cells (2HDD4 cells) were transfected with siRNA PKR or siRNA
control for 6 h. After 24 h, PKR mRNA level was measured by RT-PCR and
normalized by beta-actin mRNA level. Data are represented as mean7 SEM;
n¼3. The data are representative of two independent assays. (B) 2HDD4 cells were
transfected with either vector only control plasmid () (lane 1), PKR expression
plasmid (þ) (lane 2), non-targeting siRNA control () (lanes 3 and 5), or siRNAs
speciﬁcally targeting PKR(þ) (siRNA PKR, lanes 4 and 6) for 6 h. After overnight
incubation, an aliquot of siRNA treated 2HDD4 cells (lanes 3–6) were further
stimulated with 200 U/ml IFN-b (þ) (lanes 5 and 6) or PBS () (lanes 3 and 4). X:
no treatment. The expression of PKR protein (Row 1) and the phosphorylation of
PKR protein at Thr446 (Row 2) and Thr451 (Row 3) were analyzed by western blot
at 48 h post-treatment. Beta-actin was used as the protein loading control.Results
Inhibition of PKR enhanced the replication of HCV1a in HCV
persistently infected Huh7.5.1 cells
In order to assess the effect of PKR silencing on HCV1a replication
and infection, we constructed Huh7.5.1 cells that were persistently
infected with HCV1a (2HDD4 cells) and then investigated the effect of
PKR protein on HCV1a replication in this cell line. First, we examine
the effectiveness of siRNA PKR, siRNA PKR led to a 40% reduction of
PKR mRNA in 2HDD4 cells (p¼0.0009) (Fig. 1A) and a reduction in
PKR protein as shown by western blot (Row 1 of Fig. 1B, lanes 3 and
4). In addition, IFN-b-induced PKR phosphorylation at Thr451 and
Thr446 was inhibited by PKR silencing (Rows 2 and 3 of Fig. 1B lane4
and lane6) conﬁrming that siPKR efﬁciently suppressed PKR activa-
tion in target cells. In contrast, siRNA PKR did not have a signiﬁcant
impact on cell growth (Fig. 2A). To examine the impact of PKR
silencing on HCV1a replication, we utilized RT-PCR to monitor HCV1a
RNA replication in persistently infected 2HDD4 cells at different time
intervals after siRNA transfection. The results demonstrated that PKR
silencing increased the replication of HCV1a approximately by 1.7-
fold at day 2 (po0.0001) (Fig. 2B) and almost a 2.5-fold at day 3
(po0.0001) and resulted in the increased expression of core protein
(Fig. 2D). In contrast, over-expression of PKR in 2HDD4 cells inhibited
HCV1a replication (po0.005) (Fig. 2C). Combined, these results
indicate that PKR knockdown enhances the replication of HCV1a in
persistently infected cells.
shRNA PKR rendered Huh7.5.1 cells more susceptible to HCV1a
infection
To exclude the potential non-target effect of siRNA and to conﬁrm
the observation over a longer incubation period, we developed a
stable PKR- silenced single clone from Huh7.5.1 cells treated with a
pool of plasmids containing three PKR-target speciﬁc shRNAs. As
shown in Fig. 3A, PKR silencing signiﬁcantly suppressed double strand
RNA-induced phosphorylation of PKR at residue Thr446 and the
phosphorylation of eIF2alpha at residue Ser51, while having no
signiﬁcant impact on cell growth (Fig. 3B). Next, HCV1a RNA was
transfected into PKR silenced Huh7.5.1 cells, the results showed that
the level of HCV1a RNA replication was higher than that in control
cells (po0.001) (Fig. 3C). Furthermore, we used HCV1a virus pro-
duced from 2HDD4 cells to infect PKR silenced cells and control cells.
The number of HCV copies in PKR silenced cells was signiﬁcantly
(po0.0001) higher than that in control cells (Fig. 3D). To furtherconﬁrm the positive effect of PKR silencing on HCV1a replication, we
used PKR inhibitor, 2-aminopurine, to treat 2HDD4 cells. Similarly,
HCV1a RNA replication was enhanced by PKR inhibitor (po0.01)
(Fig. 3E).
NF-kB activation was suppressed in PKR silenced HCV1a infected and
transfected Huh7.5.1 cells
NF-kB activation has been shown to be important for PKR
function, so we examined the effects of PKR silencing on the
activation of NF-kB in HCV1a persistently infected Huh7.5.1 cells.
PKR silencing resulted in a signiﬁcant decrease in the level of NF-kB
activation (po0.0001), even after stimulation with TNF-alpha, a
known NF-kB agonist (Fig. 4A); correspondingly, a lower expression
of NF-kB protein and phosphorylated p65 protein was observed in
PKR silenced 2HDD4 cells (Fig. 4B). Consistent with these results, a
signiﬁcant inhibition of NF-kB activation and a lower expression of
NF-kB protein were also found in HCV1a RNA transfected PKR stably
silenced Huh7.5.1 cells (Fig. 4C and D). To investigate whether the
attenuation of NF-kB contributed to the enhancement of HCV1a
replication, the NF-kB inhibitor resveratrol was used. The results
showed that NF-kB inhibitor signiﬁcantly improved HCV1a RNA
replication in 2HDD4 cells (po0.005) (Fig. 4E). In composite, these
results suggest that enhanced HCV1a infection and replication are at
least partly mediated by a reduction of NF-kB activity.
Inhibition of NF-kB activation attenuated IFN-b response in PKR
silenced HCV1a infected Huh7.5.1 cells
As a downstream effector of NF-kB, the IFN-b response was
subsequently investigated in PKR silenced HCV1a infected cells.
Examining by a IFN-b reporter gene assay, ablation of PKR suppressed
Fig. 2. Inhibition of PKR enhanced the replication of HCV1a in HCV persistently
infected Huh7.5.1 cells (2HDD4 cells). (A) 2HDD4 cells were transfected with
siRNA PKR or siRNA control. After transfection, 2000 siPKR cells or 2000 siControl
cells and 2HDD4 cells were seeded in 96-well plates. The cell growth was
examined by absorbance at 450 nm as described in Materials and methods. Data
are represented as mean7 SEM; n¼6. (B) 2HDD4 cells were transfected with
siRNA PKR or siRNA control. After transfection, total cellular RNA was collected at
the indicated time points. Intracellular HCV copy numbers were measured by qRT-
PCR and normalized by beta-actin mRNA level. Data are represented as mean7
SEM; n¼6. The data are representative of four independent experiments.
(C) 2HDD4 cells were transfected with 2 mg PKR plasmid or 2 mg control plasmid
for 6 h. After transfection, total cellular RNA was collected at the indicated time
points. Intracellular HCV copy numbers were measured by qRT-PCR and normal-
ized by beta-actin mRNA level. Data are represented as mean7 SEM; n¼6. The
data are representative of four independent experiments. (D) 2HDD4 cells were
transfected with siRNA PKR or siRNA control for 6 h. After 72 h incubation, the
cellular extracts were collected and subjected to immunoblot analysis for HCV
core protein. Beta-actin was used as the protein loading control. Each sample
represents a pool of three replicates.
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After cells were transfected with HCV1a RNA, a markedly diminished
interferon beta response was found in PKR silenced cells (Po0.0001)
as compared to the control cells (Fig. 5A) and was accompanied by a
signiﬁcant (po0.0001) increase in viral replication (Fig. 5B). This
ﬁnding was further elucidated in Huh-7.5.1 cells by examining STAT1
phosphorylation after IFN-b stimulation. As shown in Fig. 5C, STAT1
protein was rapidly induced and phosphorylated following IFN-b
treatment in control cells. Conversely, inhibited expression of NF-kB,
phosphorylated p65 protein, STAT1 protein and phosphorylatedSTAT1 protein was observed in PKR stably silenced cells. These results
indicate that attenuated NF-kB activation is responsible for the
inhibition of IFN-b responses in PKR silenced Huh7.5.1 cells. To
conﬁrm that the effect of PKR silencing on interferon beta was
mediated by the inhibition of NF-kB, we introduced 2 mg of HCV1a
RNA into cells and examined STAT1 expression; PKR silencing
reduced the expression of STAT1 protein and phosphorylated STAT1
protein (Fig. 5D). Consistent with these results, PKR silencing resulted
in decreased expression of STAT1 protein and phosphorylated STAT1
protein in HCV persistently infected cells (Fig. 6A). The level of IFN-b
mRNA was also down-regulated by siRNA PKR in 2HDD4 cells
(Fig. 6B).Discussion
PKR is an important regulator of innate immunity as a sensor of
dsRNA and viral RNA, including HCV. In order to evade this response,
HCV utilizes E2 protein and NS5A protein to antagonize PKR activa-
tion (Gerotto et al., 2000; Taylor et al., 1999). Recently, the HCV
internal ribosomal entry site (IRES) also has been shown to be
involved in the inhibition of PKR (Toroney et al., 2010). Previously,
the Chisari lab had shown that HCV can hijack PKR activation to
suppress the translation of antiviral ISGs and inhibit the IFN-b-
induced antiviral response. They emphasized the important role of
PKR on the early phase of HCV2a infection (Garaigorta and Chisari,
2009). Based on these ﬁndings, it has been inferred that inhibition of
PKR activation may be an important determinant of the efﬁciency of
HCV replication. However, the inﬂuence of PKR on HCV replication is
probably complex such that in the HCV2a replicon system, HCV2a
infection has been shown to inhibit the IFN-b response through PKR
activation in RIG-I functional Huh7.25 cells. PKR inhibition can lead to
the suppression of HCV2a replication (Arnaud et al., 2010).
HCV1a is the most common genotype in the US. In this study, PKR
siRNA and PKR shRNA were used to inhibit PKR activation in an
HCV1a-replication permissive cell line, Huh7.5.1 and in an HCV1a-
persistently infected cell line, 2HDD4. After analysis by qRT-PCR, we
found that PKR down-regulation signiﬁcantly enhanced the replica-
tion of HCV1a. This is consistent with a previous report (Chang et al.,
2006), which showed that HCV RNA replication was more efﬁcient in
PKR null cells than in wild type cells. However, other studies have not
conﬁrmed this effect on HCV1a replication in Huh7.5.1 cells. Impor-
tantly, Huh7.5.1 cells carry a point mutation in the RIG-I gene which
leads to a reduction of host innate immune response to viral RNA and
renders cells more permissive to HCV1a infection (Bartenschlager and
Pietschmann, 2005; Zeisel and Baumert, 2006). This mutation mini-
mizes the effect of the RIG-I pathway on PKR activation in vivo, a
consideration in interpreting the in vitro data in this study. Moreover,
in our study, the effect of PKR silencing on HCV genotype 2a
replication was investigated using JFH1 virus. In contrast to the
ﬁnding in HCV1a virus, there was no signiﬁcant difference in virus
replication level between JFH1 virus infected PKR silenced Huh7.5.1
cells and control cells (Supplemental Fig. S1A). This result suggests
that the effect of PKR silencing on HCV replication may be genotype
speciﬁc. Then, we used JFH1/1a chimeric virus to infect Huh7.5.1 cells
with or without PKR knockdown. The results in Supplemental Fig. S1B
revealed that PKR silencing enhanced the replication of this chimeric
virus. Next, we used PKR inhibitor to treat HCV1a RNA transfected
RIG-I functional cells, IMY-4 and IMY-N9 (Date et al., 2004; Ito et al.,
2001), respectively, and monitored the replication of HCV1a virus in
these cells by RT-PCR. As shown in Supplemental Fig. S1C and D,
treatment with PKR inhibitor signiﬁcantly increased HCV1a replica-
tion in these RIG-I functional cells. Based on these results, we
concluded that PKR silencing is enhancing HCV1a replication and
this enhancement of virus replication may be genotype speciﬁc.
Fig. 3. PKR silencing rendered Huh7.5.1 cells more susceptible for HCV1a infection. (A) A stably PKR silenced Huh7.5.1 cells (shPKR) and a shRNA control plasmid
transfected Huh7.5.1 cells (shControl) were stimulated with 2 mg/ml double-strand RNA (polyI/C) by transfection with Lipofectamine 2000. Cellular extracts were collected
at the indicated time points and analyzed by western blot for PKR protein, the phosphorylation of PKR protein at Thr446, eIF2alpha protein, and the phosphorylation of
eIF2alpha protein at Ser51. Beta-actin was utilized as internal control. Each sample represents a pool of three replicates. (B) 2000 shPKR cells or 2000 shControl cells were
seeded at each well in 96-well plates. The cell growth was examined by absorbance at 450 nm as described in Materials and methods. Data are represented as mean7
SEM; n¼4. (C) 2105 shPKR cells or 2105 shControl cells were transfected with 2 mg HCV1a RNA. 72 h post-transfection, total cellular RNA was collected. Intracellular
HCV copy numbers were measured by qRT-PCR and normalized by beta-actin mRNA level. Data are represented as mean7 SEM; n¼6. The data are representative of four
independent experiments. (D) 2104 shPKR cells or 2104 shControl cells in 12-well plates were infected overnight with HCV1a virus produced from the 0.45 mm ﬁltered
culture supernatant of HCV1a persistently infected Huh7.5.1 cells (2HDD4 cells); 48 h post-infection, intracellular HCV RNA in newly infected cells was analyzed by qRT-
PCR and normalized by beta-actin mRNA copies. Data are represented as mean7 SEM; n¼3. The results are representative of two independent experiments. (E) 2HDD4
cells were treated 1 mM aminopurine or control; 48 h post-treatment, intracellular HCV RNA was analyzed by qRT-PCR and normalized by beta-actin mRNA copies. Data
are represented as mean7 SEM; n¼3. The results are representative of two independent experiments.
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interferon induction and plays an important role in the innate
immune response to HCV infection (Vilasco et al., 2006). The
study from Foy et al. (2005)showed that RIG-I mediated pathway
was disrupted by HCV protease NS3/4A in HCV-infected cells.
Moreover, HCV NS3/4A can inhibit IFN-b induction through
cleavage of IPS-1 from the membrane of mitochondria (Loo
et al., 2006). However, in the RIG-I impaired cell line, Huh7.5.1,
it is still difﬁcult to obtain high titers of HCV1a, suggesting a
possibility of a RIG-I-independent pathway involved in the hostdefense against HCV1a viral infection. PKR has been proposed as
an important modulator of type I interferon response in viral
infection and both interferon beta transcription and production
have been shown to be down-regulated by inhibition of PKR
activation in some viral infections (Carpentier et al., 2007;
Fragkoudis et al., 2008). In our study, PKR down-regulation
reduced interferon beta transcription in RIG-I nonfunctional cells.
Moreover, PKR silencing led to the reduction of interferon beta
production in HCV1a persistently infected cells. Although PKR has
no direct effect on the interferon beta transcript, PKR protein has
Fig. 4. NF-kB activation was inhibited in PKR silenced HCV1a infected Huh7.5.1 cells. (A) 2HDD4 cells were treated by transfection with siRNA Control or siRNA PKR, or
treated by a combination of siRNA with TNF-alpha (60 ng/ml) stimulation; 48 h post-treatment, the supernatants were collected and examined for NF-kB activation by
SEAP activity. Data are represented as mean7 SEM; n¼3. The results are representative of two independent experiments. (B) 2HDD4 cells were transfected with siRNA
PKR or siRNA control for 6 h. After 72 h incubation, the cellular extracts were collected and subjected to immunoblot analysis for p65 and phosphorylated p65 proteins.
Beta-actin was used as the protein loading control. Each sample represents a pool of three replicates. (C) shPKR cells and shControl cells were treated by transfection with
2 mg of HCV1a RNA, or treated by a combination of 2 mg HCV1a RNA with TNF-alpha (60 ng/ml) stimulation; 48 h post-treatment, the supernatants were collected and
examined for NF-kB activation by SEAP activity. Data are represented as mean7 SEM; n¼3. The results are representative of two independent experiments. (D) shPKR
cells and shControl cells were transfected with 2 mg of HCV1a RNA for 6 h. After 48 h incubation, the cellular extracts were collected and subjected to immunoblot analysis
for p65 and phosphorylated p65 proteins. Beta-actin was used as the protein loading control. Each sample represents a pool of three replicates. (E) 2HDD4 cells were
treated with 10 mM resveratrol, 20 mM resveratrol or DMSO. 48 h post-treatment, intracellular HCV RNA was analyzed by qRT-PCR and normalized by beta-actin mRNA
copies. Data are represented as mean7 SEM; n¼3. The results are representative of two independent experiments.
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one of the three dominant activators of interferon beta transcription.
Direct degradation of IkB by PKR protein has been proposed as an
important mechanism whereby PKR regulates NF-kB activity
(Kumar et al., 1994). In recent studies, Several viruses have been
shown to regulate interferon beta response through PKR-mediated
NF-kB activation (McAllister et al., 2010; Iwamura et al., 2001).
Huh7.5.1 cells possess a high and constant NF-kB activation, which
is an obstacle for HCV infection and replication. In our study, we didnot observe any signiﬁcant differences in the levels of eIF2alpha and
phosphorylated eIF2alpha between siRNA PKR treated and
untreated cells in a cell line (2HDD4) that was persistently infected
with HCV1a (data not shown). Also we did not ﬁnd any signiﬁcant
differences in the level of eIF2alpha and phosphorylated eIF2alpha
between 2HDD4 cells and naive cells, suggesting that the phosphor-
ylation of eIF2alpha mediated by PKR activation mainly functions on
the host against HCV infection at the early phase of viral infection.
However, we found that PKR silencing reduced NF-kB activation,
Fig. 5. siPKR silencing inhibited IFN-b response in HCV1a transfected Huh7.5.1 cells. (A) shPKR cells and shControl cells were treated by transfection with 2 mg of HCV1a
RNA or PBS. After 24 h, the cells were transfected with IFN-b reporter plasmid; 48 h post-treatment, the supernatants were collected and examined for IFN-b activation by
SEAP activity. Data are represented as mean7 SEM; n¼3. The results are representative of two independent experiments. (B) shPKR cells and shControl cells were
transfected with 2 mg of HCV1a RNA for 24 h. After that, the cells were transfected with IFN-b reporter plasmid; 48 h post-treatment, total RNA were isolated. HCV RNA
was analyzed by qRT-PCR and normalized by beta-actin mRNA copies. Data are represented as mean7 SEM; n¼3. The results are representative of two independent
experiments. (C) shPKR cells and shControl cells were stimulated with 200 u/ml IFN-b. Cellular extracts were collected at the indicated time points (minute) and analyzed
by western blot for p65 protein, the phosphorylation of p56 protein at Serine 596, STAT1 protein, and the phosphorylation of STAT1 protein at Tyr701. Beta-actin was
utilized as internal control. Each sample represents a pool of three replicates. (D) shPKR cells and shControl cells were treated by transfection with 2 mg of HCV1a RNA.
After 48 h, the cellular extracts of HCV1a transfected cells (right) and control cells (left) were collected and subjected to immunoblot analysis for core protein, STAT1
protein, and the phosphorylation of STAT1 protein at Tyr701. Beta-actin was used as the protein loading control. Each sample represents a pool of three replicates.
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Fig. 6. siPKR silencing inhibited IFN-b response in 2HDD4 cells. (A) 2HDD4 cells
were transfected with siRNA PKR or siRNA control. After 48 h, the cellular extracts
were collected and subjected to immunoblot analysis for STAT1 protein, and the
phosphorylation of STAT1 protein at Tyr701. Beta-actin was used as the protein
loading control. Each sample represents a pool of three replicates. (B) 2HDD4 cells
were treated with siRNA PKR or siRNA control. After 24 h, IFN-bmRNA levels were
examined with the relative RT-PCR and normalized with beta-actin mRNA level.
Data are represented as mean7 SEM; n¼3. The results are representative of two
independent experiments.
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core protein. Shavinskaya et al. (2007) showed that the D2 domain
of HCV core is an important determinant of viral production,
suggesting that sequence variants in this domain could affect the
host immune response to viral infection. Also, studies have docu-
mented that HCV1a core protein can signiﬁcantly suppress NF-kB
activation (Joo et al., 2005; Ray et al., 2002). Importantly, PKR
silencing resulted in the down-regulated expression of STAT1 and
the phosphorylation of STAT1. The expression of STAT1 and phos-
phorylated STAT1 has been implicated in the resistance of Type I
interferon pathway to HCV1a infection (Kanda et al., 2007;
Raychoudhuri et al., 2010).
Cumulative data suggest that the host immune response can
employ PKR activation to facilitate the translation of some ISGs to
restrict viral replication and that PKR inactivation can be used by
viruses to circumvent innate immunity (Schoggins et al., 2011).
Our data reveal the key role played by PKR in HCV1a replication
and infection and indicate that PKR silencing can suppress the
interferon beta response to HCV1a infection and replication
through NF-kB activation. In combination, these data suggest that
PKR possesses a double-face in different genotype of HCV infec-
tion; on the one side, PKR activation is utilized by HCV2a virus to
suppress the immune response, while on the other, it is involved
in the host’s innate immune response to inhibit HCV1a virus
replication and cell damage by the up-regulation of NF-kB, beta
interferon and interferon stimulated genes as well as through the
phosphorylation of eIF2alpha. These data support the concept
that NF-kB mediated type 1 interferon pathway is an important
mechanism underlying the effect of PKR silencing on HCV1areplication. Our ﬁndings provide new insight into the role of
PKR protein in HCV1a infection and suggest that PKR might be a
rational therapeutic target to enhance host immunity to HCV in
concert with protease, polymerase and other HCV-speciﬁc
enzyme inhibitors.Material and methods
Cell culture
The human hepatoma cell line, Huh7.5.1 was obtained from Dr.
Francis V. Chisari (Zhong et al., 2005). Huh7.5.1 cells were maintained
in Dulbecco’s modiﬁed Eagle’s medium (DMEM) (Gibco BRL) supple-
mented with 10% heat inactivated fetal bovine serum, 2 mM L-
glutamine, 10 mM HEPES, pH7.2, 100 unit/ml penicillin, 100 mg/ml
streptomycin, and 1% non-essential amino acids (Gibco BRL) in a
humidiﬁed 37 1C, 5% CO2 incubator. PKR knock-down Huh7.5.1 cells
and negative plasmid transfected cells were cultured in the same
medium supplemented with 1 mg/ml puromycin. The PKR inhibitor
2-aminopurine (cat. #:tlrl-apr) and the NF-kB inhibitor resveratrol
(cat. #:tlrl-resv) were purchased from Invivogen.
Construction of a HCV persistently infected cell line (2HDD4 cells)
Huh7.5.1 cells were transfected with H77S HCV RNA. At two
days post-transfection, the cells were serial diluted and seeded in
96-well plates. One clone, expressing a stable high level of HCV1a
RNA and producing infectious HCV1a, was selected as HCV
persistently infected cells (2HDD4 cells).
Construction of a stable cell line expressing PKR shRNA
Huh7.5.1 cells were transfected with a pool of 3 PKR-target
speciﬁc shRNAs (Santa Cruz, sc-36263-SH). At two days post-trans-
fection, the cells were cultured in DMEM supplemented with 1 mg/ml
puromycin. After two weeks, the remaining viable cells were serially
diluted and seeded in 96 well plates. Puromycin-resistant clones were
expanded and identiﬁed by western blot. One clone, expressing a low
level of PKR protein, was selected for further analysis.
In vitro RNA synthesis
The plasmid pH77-S, which carries a full length HCV1a sequence
with ﬁve cell culture-adaptive mutations, was kindly provided by
Dr. Stanley Lemon (Yi et al., 2006). The plasmid was linearized with
XbaI restriction enzyme and puriﬁed by Qiagen PCR puriﬁcation kit.
In vitro transcribed RNA, using the MEGA-script T7 kit (Ambion,
Austin, TX, USA), was puriﬁed with Qiagen RNA clean up kit. The
RNA pellet was aliquoted and stored at 80 1C until use.
HCV RNA transfection
HCV1a (H77S, 1 mg) full length RNA was transfected into
Huh7.5.1 cells and its derivative cells in a 6-well plate
(3105 cells/well) by using mRNA boost reagent and TranslT-
mRNA reagent (Mirus, MIR2250) according to the manufacturer’s
instructions.
Small interfering RNA transfection
With 10 nM of three PKR speciﬁc-targeting small interfering
RNAs (Santa Cruz Biotechnology, Inc, sc-36263), 2105 cells/well
in 6-well plates were transfected using Lipofectamine 2000
(Invitrogen) for 6 h. Three non-targeting, small interfering RNAs
(Santa Cruz Biotechnology, Inc, sc-37007) transfected cells were
L. Zhang et al. / Virology 438 (2013) 28–36 35used as controls. After three days incubation, cells were treated
again with speciﬁc-targeting siRNA or control siRNA for 3 days
and then analyzed.
Plasmid and transfection
Full-length expression plasmid for PKR was purchased from
Genecopoeia Inc. (Rockville, MD). Plasmid DNA (2 mg) was trans-
fected into 2105 cells/well in 6-well plates using Lipofectamine
2000 (Invitrogen) according to the manufacturer’s instructions.
Cell growth assay
Two thousand cells/well were inoculated into each well in 96-
well plates and 10 ml of the cell counting kit-8 solution (Dojindo,
CK04) were added to each well. Plates were incubated at 37 1C for
2 h. Absorbance was measured at 450 nm using a microplate
reader.
NF-kB reporter gene assay
After treatment by siRNA PKR or siRNA control, 2105 cells/
well in 6-well plates were transfected with 0.5 mg pNF-kB-SEAP-1
reporter plasmid and 10 ng pMet-Luc plasmid as internal control
for 6 h. After overnight incubation, transfected cells were stimu-
lated with TNF-alpha (60 ng/ml) or mock treated for 24 h. SEAP
and Met-Luc in the supernatant were analyzed by chemilumines-
cence as previously described (Monsurro et al., 2010).
Interferon beta reporter gene assays
With 2 mg HCV1a RNA, 3105 cells were transfected. After
overnight incubation, transfected cells were treated with 0.5 mg
pIFN-b-SEAP-1 reporter plasmid and 10 ng pMet-Luc plasmid as
internal control. Supernatant was collected at the indicated time
points. Phospha-Light
TM
SEAP Reporter Gene Assay system for
secreted alkaline phosphatase (SEAP) was obtained from Applied
Biosystems. Ready-To-Glow Secreted Luciferase Reporter system
for Metridia secreted luciferase (Met-luc) was obtained from
Clontech. SEAP and Met-Luc in the supernatant were analyzed
by chemiluminescence according to the previously described
method (Monsurro et al., 2010).
Total RNA preparation and cDNA synthesis
Total RNA was extracted from cell culture using Qiagen
RNeasy kit according the manufacturer’s instructions. RNA quan-
tity and purity were determined on a NanoDrop spectrophot-
ometer. Following the puriﬁcation of total RNA, 100 ng of RNA
was applied for cDNA synthesis using BluePrintTM RT Reagent Kit
(TAK RR737A, Takara Biochemicals). Random primers and total
RNA were incubated at 37 1C for 15 min and inactivated at 85 1C
for 5 s. cDNA was aliquoted and stored at 80 1C until utilized.
SYBR-Green real time PCR
SYBR-Green real-time PCR was carried out with a pair of forward
and reverse primers. The reaction mixture (RT-PCR kit, Code
RRO43A, Takara Biochemicals) contained 25 ml SYBR Premix Ex
Taq (2 ) (SYBRs Premix Ex TaqTM Perfect Real Time, RRO41B,
Takara Biochemicals), 1 ml of 10 mM PCR forward primer, 1 ml of
10 mM PCR reverse primer, and 100 ng cDNA to give a ﬁnal reaction
volume of 50 ml. The standard cycling conditions were 95 1C for 10 s,
followed by 40 cycles at 95 1C for 5 s, 60 1C for 30 s, with the
subsequent melting curve analysis by increasing the temperature
from 60 1C to 95 1C. IFN-b was ampliﬁed using the primers: 50-TCCTGT GGC AAT TGA ATG GG-30 and 50-TGC TCA TGA GTT TTC CCC
TGG-30; beta-actin was ampliﬁed using the primers: 50-TCACCCT-
GAAGTACCCCATC-30 and 50-TAGCACAGCCTGGATAGCAA-30. The pri-
mers to amplify PKR (sc-36263-PR) were purchased from Santa Cruz
Biotechnology (Santa Cruz, CA). The relative quantitation value of
each gene was compared to the relative quantitation value of its
matched non-treated sample. The relative quantiﬁcation values for
each gene were normalized against the endogenous housekeeping
gene beta-actin.
Quantitative RT-PCR assay
QRT-PCR for HCV RNA was performed using the primer set R6-
130-S17 (50CGGGAGAGCCATAGGTGG-30), R6-290-R19 (50-AGTACCA-
CAAGGCCTTTCG-30) and Taqman probe R6-148-S21FT (6FAM-50-
CTGCGGAACCGGTGAGTACAC-30-TAMRA). Samples were quantiﬁed
in triplicate using a TaqMan EZ RT-PCR core reagent kit (Applied
Biosystems, N808-0236). The reactions were carried out on ABI
7900HT system with a program of 50 1C for 2 min, 60 1C for
30 min, 95 1C for 4min, and then 40 cycles at 95 1C for 20 s and
60 1C for 1 min. The copies of HCV RNA were determined by in vitro
transcribed HCV1a RNA standards with the Sequence Detector Soft-
ware (version 2.2; Applied Biosystems) and normalized by beta-actin
mRNA level. Beta-actin mRNA level was quantiﬁed by in vitro
transcribed beta-actin standards with the primers: 50-AAGTGT-
GACGTGGACATCCG-30 and 50-CACACGGAGTACTTGCGCTC-30 and
Taqma probe: 6FAM-50-CTGTACGCCAACACAGTGCT-30-TAMRA.
Western blot
Twenty microgram aliquots of proteins were loaded into each
lane in 10% SDS-PAGE and then transferred to nitrocellulose
membranes. After probing with primary and second antibody,
the target proteins were developed with either TMB 1-component
membrane solution (KPL) or chemiluminescent detection. Anti-
bodies to NF-kB (C-20(p65), sc-372), beta-actin (sc-47778), PKR
(K17, sc-707), p-stat1(Tyr701)-R (sc-7988R) and stat1a p91 (C-11,
sc-417) were purchased from Santa Cruz Biotechnology (Santa
Cruz, CA); PKR (pT446) (11201) was purchased from Epitomics
(Burlingame, CA); PKR (pT451) (ab4818) was purchased from
ABcam; P-NF-kB p65 (s536) was purchased from Cell Signaling.
The relative expression of protein was normalized beta-actin
using soft Image J. The data were the means of three independent
experiments.
Statistical analysis
Data from repeated experiments were averaged and expressed
as means7the standard deviations. Statistical analysis was per-
formed by SPSS using the Student t-test or two-way Anova
analysis of variance. P values of o0.05 and o0.01 were con-
sidered statistically signiﬁcant, respectively.Acknowledgments
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